Stem Cell Therapy for Rheumatoid Arthritis
Today, new treatments and advances in Rheumatoid Arthritis research are giving new hope to people affected by Rheumatoid Arthritis. StemGenexStem Cell Research Centreprovides stem cell therapy for Rheumatoid Arthritis to help those with unmet clinical needs achieve optimum health and better quality of life. A clinical study registered through the National Institutes of Health (NIH) atwww.clinicaltrials.gov/stemgenex has been established to evaluate the quality of life changes in individuals with Rheumatoid Arthritis following stem cell therapy.
Stem cell therapy for Rheumatoid Arthritis is being studied for efficacy in improving the complications in patients through the use of their own stem cells. These Rheumatoid Arthritis therapies may help patients who dont respond to typical drug treatment, want to reduce their reliance on medication, or are looking to try stem cell therapy before starting drug treatment.
To learn more about becoming a patient and receiving stem cell therapy through StemGenex Stem Cell Research Centre, please contact one of our Patient Advocates at (800) 609-7795.Below are some frequently asked questions about stem cell treatment for Rheumatoid Arthritis.
Rheumatoid Arthritis is an autoimmune disease that attacks the bodys own tissues, specifically the synovium, a thin membrane that lines the joints. As a result of the attack, fluid builds up in the joints, causing pain in the joints and inflammation thats systemic.
Rheumatoid Arthritis (RA) is a chronic disease that can lead to long-term joint damage, resulting in chronic pain and loss of function and disability. Individuals suffering with Rheumatoid Arthritis can experience intermittent bouts of intense disease activity, called flares. In some individuals, the disease is continuously active and progressively becomes worse over time while others enjoy long periods of remission with no disease activity or symptoms. Early diagnosis and aggressive stem cell treatment for Rheumatoid Arthritis can potentially help improve patients' quality of life.
Stem cells that come from your adipose (fat) tissue have distinct functional properties including immunomodulatory and anti-inflammatory functional properties which have the capability of repairing and regenerating damaged tissue associated with disease and injury.
Upholding the highest levels of ethical conduct, safety and efficacy is our primary focus. Five clinical stem cell studies for Parkinson's Disease, Multiple Sclerosis, Osteoarthritis, Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease (COPD) are registered through the National Institutes of Health (NIH) at http://www.clinicaltrials.gov/stemgenex. Each clinical study is reviewed and approved by an independent Institutional Review Board (IRB) to ensure proper oversight and protocols are being followed.
Stem cells are the basic building blocks of human tissue and have the ability to repair, rebuild, and rejuvenate tissues in the body. When a disease or injury strikes, stem cells respond to specific signals and set about to facilitate the healing process by differentiating into specialized cells required for the bodys repair.
There are four known types of stem cells which include:
StemGenex provides autologous adult stem cells (from fat tissue) where the stem cells come from the person receiving treatment.
StemGenex provides autologous adult adipose-derived stem cells (from fat tissue) where the stem cells come from the person receiving treatment.
We tap into our bodys stem cell reserve daily to repair and replace damaged or diseased tissue. When the bodys reserve is limited and as it becomes depleted, the regenerative power of our body decreases and we succumb to disease and injury.
Three sources of stem cells from a patients body are used clinically which include adipose tissue (fat), bone marrow and peripheral blood.
Performed by Board Certified Physicians, dormant stem cells are extracted from the patients adipose tissue (fat) through a minimally invasive mini-liposuction procedure with little to no downtime.
During the liposuction procedure, a small area (typically the abdomen) is numbed with an anesthetic and patients receive mild to moderate sedation. Next, the extracted dormant stem cells are isolated from the fat and activated, and then comfortably infused back into the patient intravenously (IV) and via other directly targeted methods of administration. The out-patient procedure takes approximately four to five hours.
StemGenex provides multiple administration methods for Rheumatoid Arthritis patients to best target the disease related conditions and symptoms which include:
Since each condition and patient are unique, there is no guarantee of what results will be achieved or how quickly they may be observed. According to patient feedback, many patients report results in one to three months, however, it may take as long as six to nine months. Individuals interested in stem cell therapy are urged to consult with their physician before choosing investigational autologous adipose-derived stem cell therapy as a treatment option.
In order to determine if you are a good candidate for adult stem cell treatment, you will need to complete a medical history form which will be provided by your StemGenex Patient Advocate. Once you complete and submit your medical history form, our medical team will review your records and determine if you are a qualified candidate for adult stem cell therapy.
StemGenex team members are here to help assist and guide you through the patient process.
Patients travel to StemGenex located in Del Mar, California located in San Diego County for stem cell treatment from all over the United States, Canada and around the globe. Treatment will consist of one visit lasting a total of three days. The therapy is minimally invasive and there is little to no down time. Majority of patients fly home the day after treatment.
We provide stem cell therapy for a wide variety of diseases and conditions for which traditional treatment offers less than optimal options. Some conditions include Multiple Sclerosis, Parkinson's Disease, Rheumatoid Arthritis, Osteoarthritis and Chronic Obstructive Pulmonary Disease (COPD).
The side effects of the mini-liposuction procedure are minimal and may include but are not limited to: minor swelling, bruising and redness at the procedure site, minor fever, headache, or nausea. However, these side effects typically last no longer than 24 hours and are experienced mostly by people with sensitivity to mild anesthesia. No long-term negative side effects or risks have been reported.
The side effects of adipose-derived stem cell therapy are minimal and may include but are not limited to: infection, minor bleeding at the treatment sites and localized pain. However, these side effects typically last no longer than 24 hours. No long-term negative side effects or risks have been reported.
StemGenex provides adult stem cell treatment with mesenchymal stem cells which come from the person receiving treatment. Embryonic stem cells are typically associated with ethical and political controversies.
The FDA is currently in the process of defining a regulatory path for cellular therapies. A Scientific Workshop and Public Hearing Draft Guidances Relating to the Regulation of Human Cells, Tissues or Cellular or Tissue-Based Products was held in September 2016 at the National Institutes of Health (NIH) in Bethesda, MD. Currently, stem cell treatment is not FDA approved.
In March 2016, bipartisan legislation, the REGROW Act was introduced to the Senate and House of Representatives to develop and advance stem cell therapies.
Stem cell treatment is not covered by health insurance at this time. The cost for standard preoperative labs are included. Additional specific labs may be requested at the patients expense.
Joint inflammation is a hallmark of rheumatoid arthritis. That includes: Stiffness, Swelling, Pain, Redness and Warmth, Fatigue, Malaise, Loss of Appetite and Muscle Aches.
See more here:
Rheumatoid Arthritis Stem Cell Treatment | StemGenex
- Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer -... - November 21st, 2019
- CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia - Business Wire - November 21st, 2019
- Brooks Koepka Withdraws From Presidents Cup Team - The New York Times - November 20th, 2019
- Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2 - Science Advances - November 20th, 2019
- Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected... - November 20th, 2019
- 10 promising developments that can help Alzheimer's patients - ISRAEL21c - November 20th, 2019
- Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology - Business Wire - November 20th, 2019
- Eli Lilly touts $400M manufacturing expansion, 100 new jobs to much fanfare in Indianapolis even though it's been chopping staff - Endpoints News - November 20th, 2019
- Global Stem Cell Therapy for Osteoarthritis Market 2019 Growth Factors, Technological Innovation and Emerging Trends 2024 - News Appear - November 20th, 2019
- Shark Tank Season 11 Episode 8 Everything About Gallant Stem Cell Bank For Dogs As Seen on Shark Tank! Unknown Facts - TheNewsCrunch - November 17th, 2019
- Innovative Biosensor Technology for Stem Cells Leads Way to Treatment of Alzheimers, Parkinsons Diseases - SciTechDaily - November 17th, 2019
- These Israeli Companies Are Finding Innovative Ways To Improve Diabetes Care, Treatment | Health News - NoCamels - Israeli Innovation News - November 17th, 2019
- Cocker spaniel with cancer to receive stem cells from mother living 4,000 miles away - Fox News - November 16th, 2019
- Hip osteoarthritis: 6 ways to treat it - Medical News Today - November 16th, 2019
- Gracell Announces Five Presentations at the Annual Meeting of American Society of Hematology (ASH) - BioSpace - November 16th, 2019
- Leading Alternative Healing Director of Total Health Institute Reviews and Receives 3rd Fellowship in Stem Cell Therapy - Financialbuzz.com - November 16th, 2019
- Broncos Briefs: CB Bryce Callahan headed to surgery to replace bent screw in foot - Longmont Times-Call - November 16th, 2019
- Celgene Receives CHMP Positive Opinion for REVLIMID (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously... - November 16th, 2019
- New Cell Therapy Improves Memory and Stops Seizures Following TBI - University Herald - November 16th, 2019
- Stem Cell Therapy Market 2019 Global Industry Growth Analysis, Segmentation, Size, Share, Trend, Future Demand and Leading Players Updates by Forecast... - November 16th, 2019
- The Heart of the Matter: Leveraging Advances in Cardiac Biology to Innovate Gene-Based Therapies for Heart Failure - Physician's Weekly - November 16th, 2019
- Taiwan Announced the Application of Cell Therapy, The Value of The Medical Industry was Improved - Benzinga - November 16th, 2019
- Im grateful for the kindness of strangers in my cancer recovery - The Globe and Mail - November 16th, 2019
- Global Stem Cell Therapy Market Share, Revenue, Business Growth, Demand and Applications Market Research Report to 2029 - Trade Examiner - November 16th, 2019
- Allogene Moves Forward With CAR-T Therapy Pipeline - Seeking Alpha - November 12th, 2019
- Texan Spending Fortune, Hours A Day Trying To Live To At Least 120 Years Old: I Am My Asset - CBS Dallas / Fort Worth - November 12th, 2019
- Heart-warming moment OAP meets mum who saved his life with anonymous stem cell donation after three years of - The Sun - November 12th, 2019
- CytoDyn Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer - GlobeNewswire - November 12th, 2019
- Editas and Celgene sub Juno are tackling hottest immunotherapy cells - Endpoints News - November 12th, 2019
- Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World's First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic... - November 11th, 2019
- Triple-Drug Induction Therapy Yields Sustained Responses in Multiple Myeloma - Hematology Advisor - November 11th, 2019
- Global cell therapy market is expected to grow with a healthy CAGR over the forecast period from 2019-2025 - Yahoo Finance - November 11th, 2019
- Gary Pesselt: Vitality Healthcare is it worth the cost? - The Union of Grass Valley - November 11th, 2019
- Stem Cell Banking Market to Witness Robust Expansion throughout the Forecast 2017-2023: : Allied Market Research - GuruFocus.com - November 11th, 2019
- Cancer Stem Cells (CSCs) Market 2019 | Industry Size, Trends, Global Growth, Insights and Forecast Research Report 2025 - Business Daily Mirror - November 11th, 2019
- Stem Cell Therapy Market by Treatment,Application,End Users and Geography Forecast To 2026 - Weekly Spy - November 11th, 2019
- Ixazomib Extends Survival in Multiple Myeloma for Patients Not Treated With Stem Cell Transplantation - Pharmacy Times - November 10th, 2019
- Phase III trial of Ninlaro as first-line maintenance therapy meets PFS in multiple myeloma - The Cancer Letter - November 10th, 2019
- Roll Over Yamanaka: Meet The Cell Therapy Company Bypassing iPSCs - Scrip - November 10th, 2019
- Tears And Joy This Toddler with Down Syndrome Who Was Battling Leukemia Is Finally Cancer Free - SurvivorNet - November 10th, 2019
- Tales of medical misinformation and misadventures - Stuff.co.nz - November 10th, 2019
- AgeX Therapeutics to Present at Investing in the Age of Longevity Conference - Business Wire - November 10th, 2019
- 'My shock cancer scare and the anonymous German who saved me' - Birmingham Live - November 10th, 2019
- Laura Beil's New Podcast Bad Batch Sheds Light on the World of Unregulated Stem Cell Treatment - D Magazine - November 6th, 2019
- Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting - Business... - November 6th, 2019
- bluebird bio to Present New Data from Gene and Cell Therapy Programs at 61st American Society of Hematology Annual Meeting and Exposition - Financial... - November 6th, 2019
- Three Podcasts to Listen to in November - The New Yorker - November 6th, 2019
- Celularity to Present New Data at the ASH Annual Meeting on Novel Allogeneic, Off the Shelf, Placental Derived CAR T and NK Cell Therapy Programs -... - November 6th, 2019
- 19-28z CAR-T Therapy in Children and Young Adults With Relapsed/Refractory ALL: Promising Early Results - Cancer Therapy Advisor - November 6th, 2019
- Orchard Therapeutics to Present New Registrational Data of Investigational Gene Therapies at the 61st American Society of Hematology Annual Meeting -... - November 6th, 2019
- MD Anderson on a Roll with Another Pharma Deal, This Time with Artios and ShangPharma - BioSpace - November 6th, 2019
- Rocket Pharmaceuticals to Present Preliminary Phase 1 Data of RP-L102 Process B for Fanconi Anemia at the 61st American Society of Hematology Annual... - November 6th, 2019
- Dystrogen Therapeutics Announces That Treatment With Dystrophin Expressing Chimeric (DEC) Cells Improves Cardiac Function in Preclinical Duchenne's... - November 6th, 2019
- Transient Wave of Hematopoietic Stem Cell Production in Late Fetuses and Young Adults - Technology Networks - November 6th, 2019
- Three UCLA scientists receive grants totaling more than $18 million - UCLA Newsroom - November 4th, 2019
- Can This Cell Therapy Help Fight the NASH... - Labiotech.eu - November 4th, 2019
- Interview With Chaim Lebovits, CEO Of Brainstorm Cell Therapeutics - Seeking Alpha - November 4th, 2019
- Galera Therapeutics And Amgen In Severe Oral Mucositis - Seeking Alpha - November 4th, 2019
- The Curious Case Of Enochian Biosciences: Value Out Of Thin Air - Price Target $1 - Seeking Alpha - November 4th, 2019
- Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress - BioSpace - November 4th, 2019
- Stem Cell Banking Market Anticipated to Grow at a Significant Pace by 2028 - Weekly Spy - November 4th, 2019
- Stempeutics to receive US patent for Stempeucel - BSI bureau - November 4th, 2019
- How Stem Cells Can Heal The Body - Version Weekly - November 4th, 2019
- Light-activated pancreatic cells produce insulin on demand - New Atlas - November 4th, 2019
- Future Outlook: Animal Stem Cell Therapy Market 2019- 2025| Research Methodologies Offers High Business Outlook growth - Pledge Times - November 4th, 2019
- Surgeon banned over 'quack' procedures and 'reckless disregard' for safety - Sydney Morning Herald - November 3rd, 2019
- Five-year-old leukaemia patient Zachary White spots Nessie on dream-come-true Scotland trip - Extra.ie - November 3rd, 2019
- An Expert Discusses PARP Inhibition, Vaccines and Emerging Therapies in Kidney Cancer - Curetoday.com - November 3rd, 2019
- Leukaemia: what is it, how to spot the warning signs and who is at risk? - The Telegraph - November 3rd, 2019
- Restore your crowning glory with recombinant DNA tech - The New Paper - November 3rd, 2019
- Is blood cancer curable at an early stage? - The Indian Awaaz - November 3rd, 2019
- Stem Cell Therapy: What's Real and What's Not at California's For-Profit Clinics - UCSF News Services - November 2nd, 2019
- The Science Of Stem Cell Research Hits A Snag With Bad Batch - Forbes - November 2nd, 2019
- Mallinckrodt Announces UVADEX (Methoxsalen) Approved in Australia for use with the THERAKOS CELLEX Photopheresis System for Treatment of Chronic Graft... - November 2nd, 2019
- AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November - P&T Community - November 2nd, 2019
- Q&A: Draper's Jenna Balestrini on the future of CAR-T - - pharmaphorum - November 2nd, 2019
- Organ donations: What you can do to help save a life - Calgary Herald - November 2nd, 2019
- Six ways cancer is treated - The Standard - November 2nd, 2019
- Stem cell therapy approved for MS patients in Scotland - HeraldScotland - October 29th, 2019
- Battle brews over how tightly to regulate new cancer treatment - Crain's Detroit Business - October 29th, 2019